IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid

Leuk Lymphoma. 2018 Sep;59(9):2246-2249. doi: 10.1080/10428194.2017.1421761. Epub 2018 Jan 19.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Base Sequence
  • Carrier Proteins / genetics
  • Cell Differentiation / drug effects
  • Cell Differentiation / genetics
  • Chromosomes, Human, Pair 1
  • Chromosomes, Human, Pair 17
  • DNA-Binding Proteins
  • Humans
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukemia, Promyelocytic, Acute / genetics
  • Leukemia, Promyelocytic, Acute / pathology
  • Male
  • Neoplastic Stem Cells / drug effects*
  • Neoplastic Stem Cells / metabolism
  • Neoplastic Stem Cells / pathology
  • Nuclear Proteins / genetics
  • Oncogene Proteins, Fusion / genetics*
  • Retinoic Acid Receptor alpha / genetics
  • Transcription Factors
  • Translocation, Genetic*
  • Tretinoin / therapeutic use*
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Carrier Proteins
  • DNA-Binding Proteins
  • IRF2BP2 protein, human
  • Nuclear Proteins
  • Oncogene Proteins, Fusion
  • RARA protein, human
  • Retinoic Acid Receptor alpha
  • Transcription Factors
  • Tretinoin